Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
ValuEngine Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to Buy
08:58am, Sunday, 12'th Apr 2020
ValuEngine upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a hold rating to a buy rating in a research note issued to investors on Thursday, ValuEngine reports. ARWR has been the subje
Arrowhead Pharmaceuticals Inc:
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
11:30am, Friday, 10'th Apr 2020
Arrowhead files to begin Phase 1/2a study of ARO-ENaC, RNAi therapeutic for Cystic Fibrosis
Stocks Showing Rising Market Leadership: Arrowhead Pharma Earns 83 RS Rating
12:00am, Thursday, 09'th Apr 2020“¿Somos una Europa Unida o no? La única respuesta posible es ayudar a los países que lo necesitan”
02:42pm, Wednesday, 08'th Apr 2020
El jefe de la ciencia europea dimite en medio de la crisis desatada por el nuevo coronavirus
Norges Bank Takes Position in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
11:20am, Wednesday, 08'th Apr 2020
Norges Bank acquired a new stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund ac
Alnylam, Dicerna Join Forces to Take on Arrowhead
10:26pm, Monday, 06'th Apr 2020
Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...
Alnylam, Dicerna Join Forces to Take on Arrowhead
09:27pm, Monday, 06'th Apr 2020
Alnylam, Dicerna Join Forces to Take on Arrowhead, Stocks: ALNY,DRNA,ARWR,NTLA,VRTX,NVO,ALXN,LLY,RHHBY, release date:Apr 06, 2020
Former gene-silencing rivals bury the hatchet with new partnership
02:30pm, Monday, 06'th Apr 2020
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals Inc. both develop drugs that silence the harmful genes using an approach called RNA interference or RNAi.
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from B.Riley FBR
02:13pm, Monday, 06'th Apr 2020
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Overpaying Its CEO?
01:08pm, Saturday, 04'th Apr 2020
Chris Anzalone has been the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) since 2007. This report will, first...
Geode Capital Management LLC Grows Holdings in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
10:54am, Saturday, 04'th Apr 2020
Geode Capital Management LLC grew its stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 8.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,432
Alliancebernstein L.P. Raises Stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
08:32am, Friday, 03'rd Apr 2020
Alliancebernstein L.P. increased its holdings in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 34.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities
